<DOC>
	<DOC>NCT00353574</DOC>
	<brief_summary>This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan in subjects with resistant systolic hypertension despite treatment with full doses of three or more antihypertensive medications, including a diuretic.</brief_summary>
	<brief_title>DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LU 135252</mesh_term>
	<criteria>Subjects who have completed the Treatment Period of clinical trial DAR311 Receiving and adhering to full doses of appropriate guidelinerecommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic Subjects who discontinued treatment with study drug prior to the end of the Treatment Period of DAR311 due to a study drugrelated adverse event (AE) Treatment with another endothelin receptor antagonist within 6 months of study entry</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Resistant Hypertension</keyword>
</DOC>